trial · primary record
ADCT-701
Neuroendocrine Carcinomas
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 70 |
| Primary completion | 2029-10-30 |
| Primary endpoint | Determine the maximum tolerated dose (MTD) of ADCT-701 |
| Registry ID | NCT06041516 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:14.446Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06041516
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.